公开(公告)号：US20230416786A1

公开(公告)日：2023-12-28

申请号：US18253977

申请日：2021-11-30

Applicant: CELLECTIS SA

Inventor： Alexandre JUILLERAT ,  Philippe DUCHATEAU ,  Ming YANG

IPC: C12N15/90 ,  C12N9/22 ,  C12N15/86 ,  C07D215/46

CPC classification number: C12N15/907 ,  C12N9/22 ,  C12N15/86 ,  C07D215/46 ,  C12N2750/14143

Abstract: The invention provides aminoquinoline compounds as powerful enhancers of genetic recombination in living cells, especially to perform site-directed gene integration of exogenous DNA template by homologous recombination. In particular, disclosed are methods by which cells are treated with chloroquine and/or hydroxychloroquine prior to, or concomitantly with, the introduction of exogenous DNA templates, and optionally in presence of rare-cutting endonucleases, to obtain higher rates of gene integration or correction.

公开(公告)号：US20230248825A1

公开(公告)日：2023-08-10

申请号：US18005284

申请日：2021-07-23

Applicant: CELLECTIS S.A.

Inventor： Shipra DAS ,  Sumin JO ,  Alexandre JUILLERAT ,  Julien VALTON ,  Laurent POIROT ,  Philippe DUCHATEAU

IPC: A61K39/00 ,  C12N9/22 ,  C12N15/11 ,  C12N15/90 ,  C12N5/0783 ,  C12N15/113 ,  A61K39/395 ,  A61P35/00

CPC classification number: A61K39/4633 ,  C12N9/22 ,  C12N15/11 ,  C12N15/907 ,  C12N5/0636 ,  A61K39/4611 ,  A61K39/4643 ,  C12N15/1138 ,  A61K39/3955 ,  A61K39/4631 ,  A61P35/00 ,  C12N2800/80 ,  C12N2310/20 ,  C12N2506/11 ,  C12N2501/515 ,  C12N2501/51 ,  C12N2501/2302 ,  A61K2039/5158 ,  C12N2310/531 ,  C12N2310/14

Abstract: The invention relates to therapeutic compositions for allogeneic cellular therapy comprising TCR deficient T-cells, which are genetically engineered to express immune cell engagers, and methods related thereto.

公开(公告)号：US20200332004A1

公开(公告)日：2020-10-22

申请号：US16958250

申请日：2018-12-28

Applicant: CELLECTIS

Inventor： Alex BOYNE ,  Laurent POIROT ,  Philippe DUCHATEAU ,  Alexandre JUILLERAT

IPC: C07K16/28 ,  C12N5/0783 ,  C12N15/87 ,  C12N15/86 ,  A61K35/17 ,  A61P35/00

Abstract: A method for engineering less alloreactive immune cells, including T-cells that express chimeric antigen receptors (CARs), using a nucleotide sequence in form of an RNA encoding a anti-TCR CAR to achieve the transient expression of anti-TCR CAR at the cell surface. The transient expression of the anti-TCR CAR recognized by the alpha beta TCR on the cell surface unexpectedly enabled the a purification of the TCR-negative CAR expressing cells. The TCR-negative CAR expressing immune cells can be used in adoptive therapy to treat diseases associated with cell surface antigens, such as cancer with less side effects, in particular less GVHD.

公开(公告)号：US20180237533A1

公开(公告)日：2018-08-23

申请号：US15752195

申请日：2016-08-24

Applicant: CELLECTIS

Inventor： Alexandre JUILLERAT ,  Philippe DUCHATEAU ,  Laurent POIROT

IPC: C07K16/28 ,  A61K31/436 ,  A61K35/17 ,  C07K14/72 ,  A61P35/00

CPC classification number: C07K16/2869 ,  A61K31/436 ,  A61K35/17 ,  A61K38/00 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/721 ,  C07K16/2803 ,  C07K2317/622 ,  C07K2319/03 ,  C12N2510/00

Abstract: The present invention relates to the field of cell immunotherapy and more particularly to a new generation of chimeric antigen receptors (CAR), allowing the control of immune cells endowed with such CARs through the interaction with small molecules. More particularly, the present invention relates to chimeric antigen receptor which comprise in at least one ectodomain a molecular switch turning the antigen binding function of the receptor from an off to on state, and vice versa. The present invention thus provides more controlled and potentially safer engineered CAR endowed immune cells, such as T-lymphocytes.

公开(公告)号：US20170296623A1

公开(公告)日：2017-10-19

申请号：US15532430

申请日：2015-12-17

Applicant: CELLECTIS

Inventor： Alexandre JUILLERAT ,  Philippe DUCHATEAU ,  Laurent POIROT

IPC: A61K38/17 ,  C07K14/47 ,  C07K14/705 ,  C07K14/525 ,  A61K38/00 ,  C07K14/00

CPC classification number: A61K38/17 ,  A61K35/17 ,  A61K38/00 ,  A61K39/395 ,  A61K2039/505 ,  A61K2039/507 ,  C07K14/00 ,  C07K14/4748 ,  C07K14/525 ,  C07K14/70596 ,  C07K16/2878 ,  C07K16/2887 ,  C07K16/3069 ,  C07K2319/00

Abstract: The invention relates to negative T-cell signal inducing chimeric antigen receptor (N-CAR or i-CAR) and to T-cells comprising such N-CAR as well as a positive T-cell signal inducing CAR (P-CAR) as well as their use in therapy.

公开(公告)号：US20170292118A1

公开(公告)日：2017-10-12

申请号：US15517708

申请日：2015-10-07

Applicant: CELLECTIS

Inventor： Philippe DUCHATEAU ,  Alexandre JUILLERAT ,  Laurent POIROT

IPC: C12N5/16 ,  C12N5/078 ,  C12N15/87 ,  C07K14/725 ,  C12N15/02 ,  C12N5/07 ,  C07K14/705

CPC classification number: C12N5/163 ,  C07K14/705 ,  C07K14/7051 ,  C07K2317/622 ,  C07K2319/01 ,  C07K2319/03 ,  C07K2319/70 ,  C07K2319/74 ,  C12N5/06 ,  C12N5/0634 ,  C12N5/0636 ,  C12N5/10 ,  C12N15/02 ,  C12N15/87

Abstract: The present invention relates to a method to modulate the level of activation of an engineered immune cell (such as a Chimeric Antigen Receptor T-cell) for immunotherapy. The present invention also relates to cells obtained by the present method, preferably comprising said modulable/tunable chimeric antigen receptors for use in therapeutic or prophylactic treatment.

公开(公告)号：US20160355875A1

公开(公告)日：2016-12-08

申请号：US15028644

申请日：2014-10-10

Applicant: CELLECTIS

Inventor： Julien VALTON ,  Alexandre JUILLERAT ,  Fayza DABOUSSI ,  Marine BEURDELEY ,  Claudia BERTONATI ,  Philippe DUCHATEAU

IPC: C12Q1/68 ,  G01N33/53

CPC classification number: C12Q1/6816 ,  C12Q1/6806 ,  C12Q1/6827 ,  C12Q1/6841 ,  G01N33/5308 ,  C12Q2522/101 ,  C12Q2565/531

Abstract: The present invention relates to a method for the detection of a specific nucleic acid. Specifically, the invention provides a method and kits for detecting the presence of a specific nucleic acid using engineered DNA-binding domains such as Transcription Activator Like-Effector (TALE) domain or modular base-per-base binding domains (MBBBD). The method of the invention is particularly useful for in vitro diagnostic application.

Abstract translation: 本发明涉及用于检测特定核酸的方法。 具体地，本发明提供了使用工程化的DNA结合结构域如转录激活子效应（TALE）结构域或模块化碱基结合结构域（MBBBD）来检测特异性核酸的存在的方法和试剂盒。 本发明的方法对于体外诊断应用特别有用。